Articles

Following the press release on December 15 regarding the Vps34 program, Redeye's analysts ask some questions to Sprint Biosciences CEO, Johan Emilsson. The interview is also available at Redeye. Why is Deciphera returning the program? According to the agreement, they have the right to return the program without specifying any reason and they have chosen not to go public with the reason. May this...

Johan Emilsson, newly appointed CEO of Sprint Bioscience, answers questions #femsnabba at Börsvärlden about the company's success in a tough, competitive market. The company is driven by demonstrating how effective drug development can be with the right attitude and skills, and by improving the lives of those affected by cancer. Johan Emilsson, you are the new CEO of Sprint Bioscience since [...]

See what has been written about Sprint Bioscience regarding the news of the VADA agreement: Fierce BiotechDaily IndustryBusiness WorldBioStock Börsronden v 33Pharmaceutical market - industry coverage from Dagens MedicinLifeScience SwedenNordic Life Science News

Sprint Biosciences acting CEO Mathias Skalmstad visited Redeye's studio and answered questions regarding the license agreement for the VADA program. Press releaseComment from Redeye on the agreement